FORMS AND SEVERITY LEVELS OF EMOTIONAL-VOLITIONAL DEFICIT IN PARANOID SCHIZOPHRENIA AND THEIR CLINICAL-DYNAMIC CHARACTERISTICS (LITERATURE REVIEW)
Keywords:
schizophrenia, emotional-volitional deficit, cognitive impairments, progressive course, clinical forms, dynamics, adaptationAbstract
This article provides a comprehensive analysis of the concept of emotional-volitional deficit (EVD) as a core pathogenetic mechanism of schizophrenia. The author substantiates-on both theoretical and practical grounds-the natural essence of EVD, its clinical forms, severity levels, and dynamics. Schizophrenia is interpreted as an adaptive condition that strives to preserve internal equilibrium by transitioning to a lower energy level of functioning. The paper highlights how EVD deepens as a progressive process, its interrelationship with cognitive impairments, and its functional consequences. It also critiques the absence of a severity classification for EVD in ICD-10 and argues for introducing such clinical criteria into Medical and Social Expertise (MSE) and forensic-psychiatric practice.
References
Alimdjanovich, R. J., & Astanovich, A. A. (2023). Development of dental care in uzbekistan using a conceptual approach to improve its quality. Central Asian Journal of Medical and Natural Science, 4(4), 536-543.
Alimdjanovich, R. J., Abdujamilevich, S. A., & Bakhriddnovich, T. A. (2021). The State of Periodontal Tissues in Athletes Engaged in Cyclic Sports. Annals of the Romanian Society for Cell Biology, 25(1), 235-241.
Andreasen, N. C., Carpenter Jr, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry, 162(3), 441-449.
Barch, D. M., & Ceaser, A. (2012). Cognition in schizophrenia: core psychological and neural mechanisms. Trends in cognitive sciences, 16(1), 27-34.
Cannon, W. B. (1929). Organization for physiological homeostasis. Physiological reviews, 9(3), 399-431.
Castellanos, J. F. G., Jiménez, M. R., Chang, A. J. B., Pelayo, A. M. Z., & Meza, E. A. C. (2023). Más allá de lo habitual: Nuevos enfoques en la terapia de la esquizofrenia resistente. Archives of Evidence-Based Medicine, 1(2), 37-55.
Fusar-Poli P., Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [18F/11C]-DOPA PET studies //Schizophrenia bulletin. – 2013. – Т. 39. – №. 1. – С. 33-42.
Green, M. F. (2016). Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia.
Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophrenia bulletin, 35(3), 549-562.
Insel, T. R. (2010). Rethinking schizophrenia. Nature, 468(7321), 187-193.
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., ... & Insel, T. R. (2015). Schizophrenia (primer). Nature Reviews. Disease Primers, 1(1).
Keefe, R. S., & Harvey, P. D. (2012). Cognitive impairment in schizophrenia. Novel antischizophrenia treatments, 11-37.
Kirkpatrick, B., Fenton, W. S., Carpenter Jr, W. T., & Marder, S. R. (2006). The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia bulletin, 32(2), 214-219.
Leonchuk, S. L., & Leonchuk, S. S. (2017). Emotional Volitional Defect—Quintessence of Schizophrenia. Acta Psychopathol, 3, 3.
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., ... & Young, L. J. (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature reviews Drug discovery, 11(2), 141-168.
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014). Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. European neuropsychopharmacology, 24(5), 645-692.
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular psychiatry, 17(12), 1206-1227.
